Copyright © Inderes 2011 - present. All rights reserved.

Pharma Equity Group

0.10 DKK

-12.89 %

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-12.89 %
-12.50 %
+4.93 %
-9.68 %
-20.33 %
-36.57 %
-86.20 %
-79.48 %
-99.62 %

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more
Market cap
120.3M DKK
Turnover
79.43K DKK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 10.09.2025

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.3
2026

Annual report '25

16.4
2026

General meeting '26

14.8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pharma Equity Group (PEG) - Signs Letter of Intent (LOI) to acquire MedTech company Otiom
Analyst Comment by
Philip Coombes

Pharma Equity Group (PEG) - Signs Letter of Intent (LOI) to acquire MedTech company Otiom

Pharma Equity Group (PEG) has taken the first tangible step in executing its diversification strategy announced in May 2025 by signing a Letter of Intent (LOI) to acquire Otiom A/S, a Danish MedTech company specializing in IoT-based localization technology for people with dementia. The transaction marks PEG’s initial expansion beyond pharmaceuticals into commercial-stage MedTech and aligns with CEO Christian Tange’s (new CEO from 1 April 2025) ambition to become a Nordic life sciences consolidator.

Pharma Equity Group
Pharma Equity Group: PEG restrukturerer gæld gennem nye konvertible lån
Analyst Comment by
Philip Coombes

Pharma Equity Group: PEG restrukturerer gæld gennem nye konvertible lån

Pharma Equity Group har konsolideret sin finansieringsstruktur ved at udstede nye konvertible lån på DKK 10,9 mio. den 1. oktober 2025, hvorved de tidligere lån fra april og juli 2025 samt en udnyttet kreditfacilitet refinansieres. Det nye konvertible lån har samme årlige rente på 10% som udstedelsen i juli 2025, men udvider konverteringsvinduet, der nu åbner om 23 måneder (september 2027).

Pharma Equity Group
Pharma Equity Group: Video med præsentation af Reponex pipeline
Analyst Comment

Pharma Equity Group: Video med præsentation af Reponex pipeline

Efter myndighedsgodkendelsen til fase 2-studiet med RNX-011(livstruende bughindebetændelse) vil Reponex direktør Sebastian Bo Jakobsen gennemgår næste fase af studiet og hvad godkendelsen indebærer. Derudover vil CEO i Pharma Equity Group Christian Tange gennemgå kommercialiseringsmulighederne for RNX-011.

Pharma Equity Group
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.